MD-PATTON-ELECTRONICS
13.9.2016 15:04:14 CEST | Business Wire | Press release
Patton Electronics —US manufacturer of UC, cloud, and IoT enabling solutions for carrier, enterprise and industrial networks—is now shipping a new line of cost-effective, high-performance SmartNode enterprise session border controllers (eSBC) that offer two to eight integrated telephony interfaces.
A typical eSBC provides All-IP, SIP-to-SIP communication only , whereas conversion from traditional analog or ISDN to IP telephony remains the job of a separate VoIP Media gateway. By merging media gateway functions with high-end eSBC capabilities in a single, low-cost, customer-premise device, Patton’s innovation accelerates obsolesce of the traditional Analog Telephone Adapter (ATA).
The new VoIP CPE are designed for small-businesses/small-offices that need to integrate legacy phones, fax machines, meters, postage machines, or POTS/ISDN trunks into ALL-IP communication systems, including on-premise and hosted UC solutions.
The SN5541 offers 2, 4 or 8 FXS ports . The SN4151 offers flexible combinations of 2 to 8 FXS & BRI ports.
“The world is going ALL-IP,” said Burton A. Patton, EVP. “Cloud Telephony remains on the rise. In order to achieve convergence, many enterprises proliferate their on-premise devices. In one box, a Patton eSBC does the job of two, three, or more devices—at half the cost of alternative solutions.”
For businesses with immediate FXS/BRI media conversion requirements: Patton’s SmartNode 4141 VoIP gateway has got you covered. Offering license-key conversion to rich-featured eSBC functionality, the SN4141 also supports inevitable migration to SIP-trunking, unified communications (UC), hosted or cloud-based services.
Carrier Class. Patton’s carrier-grade dual image feature—rarely found in low-port-count CPE—provides fallback/recovery capability for service continuity during network-wide software upgrade.
Fully Loaded. New SmartNode eSBCs include such state-of-the-art features as SRTP/TLS security, USB cell-modem support, PSTN redundancy, 3G/4G fail-over/survivability, generic routing encapsulation (GRE tunneling), border gateway protocol (BGP).
They also boast the VoIP industry’s longest-reach FXS local loop (10 kilometers at 3 REN)—useful for such applications as off-premise extension.
A built-in BroadSoft PacketSmart Probe for network-monitoring is available.
Last month Patton announced CopperLink™ 1101 PoE Extender kits that leverage copper or coaxial cable to deliver Power-over-Ethernet up to 3,000 feet.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160913005076/en/
Contact:
Patton
Glendon Flowers, +1 301-975-1000
press@patton.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom